Dose discordance of direct acting oral anticoagulants using different equations for estimating GFR: a literature review

References

• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Eur Heart J. 2018;39(8):1330–1393.
   PubMedGoogle Scholar
• Hepburn-Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism: a concise review of diagnosis and management. Intern Med J. 2019;49(1):15–27.
   PubMed Web of Science ®Google Scholar
• Nimmo C, Wright M, Goldsmith D. Management of atrial fibrillation in chronic kidney disease: double trouble. Am Heart J. 2013;166(2):230–239.
   PubMed Web of Science ®Google Scholar
• Fanikos J, Burnett AE, Mahan CE, et al. Renal function considerations for stroke prevention in atrial fibrillation. Am J Med. 2017;130:1015–1023.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Spruill WJ, Wade WE, Iii HHC. Continuing the use of the cockcroft – gault equation for drug dosing in patients with impaired renal function. Clin Pharmacol Ther. 2009;86(5):468–470.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study. Am J Kidney Dis. 2010;56(3):486–495.
   PubMed Web of Science ®Google Scholar
• Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther. 2017;102(3):405–419.
   PubMed Web of Science ®Google Scholar
• Noormohamed NZ, Gao W, Rizk ML. A systematic review of renal function estimation equations. Curr Pharmacol Rep. 2019;5:359–376.
   Google Scholar
• Eknoyan G, Lameire N, Eckardt K, et al. KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int (Suppl). 2013;3:1–150.
   Web of Science ®Google Scholar
• FDA. Pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling. 2010.
   Google Scholar
• European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function (EMA/CHMP/83874/2014). [ cited 2020 July 12]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf
   Google Scholar
• MacCallum PK, Mathur R, Hull SA, et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. Br Med J. 2013;3:1–7.
   Web of Science ®Google Scholar
• Kruger PC, Robinson MA, Xu K, et al. Assessing renal function in patients receiving DOACs: cockcroft-gault versus estimated glomerular filtration rate. Thromb Res. 2017;157:165–166.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183(2):170–184.
   PubMed Web of Science ®Google Scholar
• Shroff GR. Renal function in patients with atrial fibrillation receiving anticoagulants. JAMA Cardiol. 2016;1(4):375–376.
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Peterson ED, Piccini JP. When less is not more. J Am Coll Cardiol. 2017;69(23):2791–2793.
   PubMed Web of Science ®Google Scholar
• Moranville MP, Jennings HR. Implications of using modification of diet in renal disease versus Cockcroft-Gault equations for renal dosing adjustments. Am J Health Syst Pharm. 2009;66(2):154–161.
   PubMed Web of Science ®Google Scholar
• Malavasi VL, Pettorelli D, Fantecchi E, et al. Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function: post hoc analysis of a prospective cohort. Intern Emerg Med. 2018;13(7):1059–1067.
   PubMed Web of Science ®Google Scholar
• Andrade JG, Hawkins NM, Fordyce CB, et al. Variability in NOAC dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae. Can J Cardiol. 2018;34(8):1010–1018.
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Andreu-Cayuelas JM, Marín F, et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (English Ed.). 2014;68(6):497–504.
   PubMed Web of Science ®Google Scholar
• Ahlert D, Wynn E, Thomas H. Abstract of “Appropriate DOAC dosing: an evaluation for real world cardiology”. Heart. 2018;104:A28–9.
   Web of Science ®Google Scholar
• Chen Y-T, Lin H-J. Renal function estimates and dosing of direct oral anticoagulants in stroke patients with atrial fibrillation: an observational study. Acta Neurol Taiwan. 2018;27(2):39–44.
   PubMedGoogle Scholar
• Gerchman F, Tong J, Kristina MU, et al. Superiority of the modification of diet in renal disease equation over the cockcroft-gault equation in screening for impaired kidney function in japanese americans. Diabetes Res Clin Pract. 2007;77(2):320–326.
   PubMed Web of Science ®Google Scholar
• Lum DOCJ, Azuma S. A comparison of methods for estimating glomerular filtration rate for a population in Hawai’i with non-valvular atrial fibrillation. Hawaii J Med Public Health. 2013;72(9 Suppl 4):27–29.
   PubMedGoogle Scholar
• Kucey M, Bolt J, Albers L, et al. Prescribing of direct oral anticoagulants in atrial fibrillation based on estimation of renal function using standard and modified cockcroft-gault equations: a retrospective analysis. Can J Hosp Pharm. 2016;69(5):409–414.
   PubMed Web of Science ®Google Scholar
• Kantorovich A. Renal function and direct oral anticoagulant dose reduction. Am J Med. 2017;130(8):e363.
   PubMed Web of Science ®Google Scholar
• Loo SY, Coulombe J, Dell’Aniello S, et al. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ. 2018;8(1):1–9.
   Web of Science ®Google Scholar
• Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637–645.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–51.
   PubMed Web of Science ®Google Scholar
• Pérez Cabeza AI, Chinchurreta Capote PA, González Correa JA, et al. Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. Med Clin (Barc). 2018;150(3):85–91.
   PubMed Web of Science ®Google Scholar
• Seidi M, Patel J, Czuprynska J, et al. Abstract of “Method of renal function estimation influences accuracy of DOAC prescribing.”. Br J Haematol. 2016;POSTER SES:64.
   Google Scholar
• Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017;10:135–143.
   PubMed Web of Science ®Google Scholar
• Helldén A, Odar-Cederlöf I, Nilsson G, et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ [Internet]. 2013;3 [cited 2020 July 12]. Available from: http://bmjopen.bmj.com
   PubMed Web of Science ®Google Scholar
• Schwartz JB. Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct oral anticoagulants. J Am Geriatr Soc. 2016;64(10):1996–2002.
   PubMed Web of Science ®Google Scholar
• Weir MR, Kreutz R. Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non–vitamin K antagonist oral anticoagulants. Mayo Clin Proc. 2018;93(10):1503–1519.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that Inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641–655.
   PubMed Web of Science ®Google Scholar
• Savaysa [package insert]. Parsippany (NJ): Daiichi Sankyo; 2015;1–35. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206316s004lbl.pdf
   Google Scholar
• Hawkins NM, Jhund PS, Pozzi A, et al. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail. 2016;18(9):1162–1171.
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Shrader P, Thomas L, et al. Influence of kidney function estimation methods on eligibility for edoxaban population impact of the US food and drug administration’s approach for its product labeling. Circulation. 2016;134(15):1122–1124.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016;134(1):24–36.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, Agostino RBD, et al. Impact of atrial fibrillation on the risk of death the framingham heart study. Circulation. 1998;98:946–952.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG. Atrial fibrillation and chronic kidney disease : a bad combination. Kidney Res Clin Pract. 2018;37(2):103–105.
   PubMed Web of Science ®Google Scholar
• Zeng W, Sun X, Tang K, et al. Risk of thromboembolic event in atrial fibrillation with chronic kidney disease. Stroke. 2015;183:157–163.
   Google Scholar
• Ravera M, Bussalino E, Paoletti E, et al. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: do we need a novel risk score calculator? Int J Cardiol. 2019;274:179–185.
   PubMed Web of Science ®Google Scholar
• Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD- EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003–1009.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD- EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622–627.
   PubMed Web of Science ®Google Scholar